Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $13.31 Consensus Target Price from Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have received an average rating of "Hold" from the twelve analysts that are presently covering the firm, Marketbeat.com reports. Twelve research analysts have rated the stock with a hold recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $13.31.

Several research firms have issued reports on PLRX. Oppenheimer reaffirmed a "market perform" rating on shares of Pliant Therapeutics in a report on Monday, February 10th. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $4.00 price target (down from $43.00) on shares of Pliant Therapeutics in a report on Monday, February 10th. JPMorgan Chase & Co. lowered shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, February 10th. HC Wainwright reaffirmed a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 18th. Finally, Stifel Nicolaus lowered shares of Pliant Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, March 3rd.

Institutional Investors Weigh In On Pliant Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its holdings in Pliant Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company's stock valued at $170,000 after purchasing an additional 1,209 shares during the last quarter. Swiss National Bank boosted its holdings in Pliant Therapeutics by 1.6% in the fourth quarter. Swiss National Bank now owns 95,700 shares of the company's stock valued at $1,260,000 after purchasing an additional 1,500 shares during the last quarter. Atria Investments Inc boosted its holdings in Pliant Therapeutics by 18.1% in the fourth quarter. Atria Investments Inc now owns 11,821 shares of the company's stock valued at $156,000 after purchasing an additional 1,812 shares during the last quarter. R Squared Ltd purchased a new stake in Pliant Therapeutics in the fourth quarter valued at $33,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pliant Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock valued at $6,050,000 after purchasing an additional 2,721 shares during the last quarter. 97.30% of the stock is owned by hedge funds and other institutional investors.

Pliant Therapeutics Stock Down 0.8%

NASDAQ:PLRX traded down $0.01 during trading hours on Thursday, reaching $1.28. The company's stock had a trading volume of 885,268 shares, compared to its average volume of 1,098,053. The company has a market capitalization of $78.57 million, a P/E ratio of -0.38 and a beta of 1.43. Pliant Therapeutics has a 12 month low of $1.10 and a 12 month high of $16.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The stock has a 50 day moving average price of $1.42 and a two-hundred day moving average price of $6.74.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17. Equities analysts predict that Pliant Therapeutics will post -3.64 EPS for the current fiscal year.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.